Lindsey Shapiro PhD, science writer —

Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.

Articles by Lindsey Shapiro

1st approved Symbicort generic, Breyna, now available in US

Breyna, a generic version of Symbicort (budesonide-formoterol), has been launched in the U.S. for eligible people with chronic obstructive pulmonary disease (COPD) and asthma. The inhaled medication — the first Symbicort generic to be approved by the U.S. Food and Drug Administration — will become immediately available…

Dupixent found to prevent COPD exacerbations in Phase 3 trial

Dupixent (dupilumab) — a medication initially approved for exzema — was found to significantly reduce the number of disease exacerbations and to improve lung function in people with chronic obstructive pulmonary disease (COPD), meeting the primary and key secondary goals of the pivotal Phase 3 BOREAS trial. A similarly…

COPD-related Deaths Rising in Women, Declining in Men

Mortality rates associated with chronic obstructive pulmonary disease (COPD) were declining in men but rising among women in many countries as of 2019, according to a recent study. This shift is likely related to changes in smoking habits, with smoking generally declining in men but being more variable among…